ライフサイエンスコーパス: BDA

1 BDA did not label the nearby C1 cells.

2 BDA injection in the lateral part of the lateral parafas

3 BDA injection in the medial parafascicular nucleus and t

4 BDA injection in the medial part of the lateral parafasc

5 BDA positive cases showed a marked accumulation of poor

6 BDA was iontophoresed unilaterally into the caudal Vme,

7 BDA-366 suppresses growth of lung cancer xenografts deri

8 BDA-366-Bcl2 binding induces conformational change in Bc

9 BDA-ir varicosities were found in the solitary tract nuc

10 BDA-labeled fibers from the SCN and vSPVZ formed apposit

11 BDA-labeled projection neurons varied widely in the shap

12 BDA-labeled terminals often apposed MOR-immunoreactive d

13 BDA-labeled terminals were closely apposed upon HRP retr

14 A total of 1408 BDA-labeled boutons were examined ultrastructurally, whi

15 Of the 1408 BDA-labeled boutons, 69.6% of them were S-type boutons c

16 exhibited at least one close contact with a BDA-labeled vagal bouton, although most of these cells r

17 Using a Bax degradation activity (BDA) assay, CLL cells were found to show variable Bax in

18 osome (Chr) 4 for the renal traits, adjusted BDA, and cholangitis with logarithm of odds scores of 18

19 r the left parietal cortex immediately after BDA injections.

20 for MOR were seen in 14% (134 of 938) of all BDA-labeled axons and axon terminals.

21 of a mixture of biotinylated dextran amine (BDA) and (3)H-leucine was made into the marginal shell o

22 present study employed biotin dextran amine (BDA) and cholera toxin B subunit (CTB) as anterograde an

23 e group of rats, biotinylated dextran amine (BDA) and Fluoro-Ruby (FR) were injected into separate ba

24 erograde tracers biotinylated dextran amine (BDA) and fluoro-ruby (FR) were injected into separate pa

25 erograde tracers biotinylated dextran amine (BDA) and fluoro-ruby (FR) were injected into the whisker

26 erograde tracers biotinylated dextran amine (BDA) and fluoro-ruby (FR) were injected into the whisker

27 erograde tracers biotinylated dextran amine (BDA) and fluororuby (FR) were injected into the whisker

28 al labeling with biotinylated dextran amine (BDA) and identifying patch and matrix in the same sectio

29 rograde tracers, biotinylated dextran amine (BDA) and Phaseolus vulgaris-leucoagglutinin (PHA-L), int

30 tudied using the biotinylated dextran amine (BDA) anterograde tracing method in the rat.

31 c tracers such a biotinylated dextran amine (BDA) are used to label regenerating fibers after therape

32 ll injections of biotinylated dextran amine (BDA) as an anterograde tracer in various parts of the DS

33 By using biotinylated dextran amine (BDA) as anterograde tracer, we characterized the topogra

34 ade transport of biotinylated dextran amine (BDA) following injections into the rat prefrontal cortex

35 hus, we injected biotinylated dextran amine (BDA) in CRNs to study their projections with light and e

36 terograde tracer biotinylated dextran amine (BDA) in lactating rats and DIO mice.

37 etic deposits of biotinylated dextran amine (BDA) in the area of the rVRG, many BDA-labeled terminals

38 ns of the tracer biotinylated dextran amine (BDA) in the dorsal lateral geniculate nucleus (dLGN) of

39 etrogradely with biotinylated dextran amine (BDA) injected into the visual cortex.

40 Gross biocytin/biotinylated dextran amine (BDA) injections into the SG or extrastriate cortex label

41 s, at which time biotinylated dextran amine (BDA) injections were made into the SI.

42 terograde tracer biotinylated dextran amine (BDA) into 126 sites centered about the right lower extre

43 Injections of biotinylated dextran amine (BDA) into Av labeled both afferent terminals and neurons

44 ng injections of biotinylated dextran amine (BDA) into cortical area 17, two types of corticothalamic

45 natomical tracer biotinylated dextran amine (BDA) into different tonotopic regions of the LSO of albi

46 de injections of biotinylated dextran amine (BDA) into layer 3 of macaque prefrontal area 9 and exami

47 terograde tracer biotinylated dextran amine (BDA) into layers 2-5 of each area, labelled axonal varic

48 Injection of biotinylated dextran amine (BDA) into physiologically identified shoulder responsive

49 ll injections of biotinylated dextran amine (BDA) into SI barrel cortex.

50 We injected biotinylated dextran amine (BDA) into single vibrissal 'barrels' of primary somatose

51 Injections of biotinylated dextran amine (BDA) into the dorsal cochlear nucleus (DCN) of the rat l

52 terograde tracer biotinylated dextran amine (BDA) into the heterotopic cortex.

53 Injections of biotinylated dextran amine (BDA) into the InC anterogradely labeled axons that termi

54 ve axonal tracer biotinylated dextran amine (BDA) into the left nodose ganglion in rats.

55 terograde tracer biotinylated dextran amine (BDA) into the medial preoptic (MPO) produced dense label

56 cers biocytin or biotinylated dextran amine (BDA) into the MGV labeled thalamocortical afferent patch

57 Injection of biotinylated dextran amine (BDA) into the PVH produced clusters of BDA-positive nerv

58 nt injections of biotinylated dextran amine (BDA) into the right motor cortex.

59 ced by injecting biotinylated dextran amine (BDA) into the sensorimotor cortex of one hemisphere eith

60 xidase (HRP) and biotinylated dextran amine (BDA) into the utricular macula; and 2) to investigate th

61 acing, either by biotinylated dextran amine (BDA) labeled with immunogold-silver or by degeneration a

62 ade transport of biotinylated dextran amine (BDA) or Phaselous leucoagglutinin placed in the superior

63 dase labeling of biotinylated dextran amine (BDA) or Phaseolus vulgaris-leucoagglutinin (PHA-L) from

64 Injections of biotinylated dextran amine (BDA) that included this caudomedial riMLF region anterog

65 iculus (SC) with biotinylated dextran amine (BDA) to backfill retinal axons, which also project to th

66 ade transport of biotinylated dextran amine (BDA) to identify dendrites of forward-projecting neurons

67 terograde tracer biotinylated dextran amine (BDA) to investigate intra-SCN connectivity and the neura

68 of anterogradely biotinylated dextran amine (BDA) tracing combined with retrogradely horseradish pero

69 n (WGA-HRP) with biotinylated dextran amine (BDA) transport.

70 injection of 10% biotinylated dextran amine (BDA) unilaterally into the Vsup anterogradely labeled ax

71 Biotinylated dextran amine (BDA) was initially iontophoresed into the dorsal part of

72 terograde tracer biotinylated dextran amine (BDA) was injected into the lumbosacral dorsal gray commi

73 Biotinylated dextran amine (BDA) was injected into the right sensorimotor cortex to

74 erograde tracer, biotinylated dextran amine (BDA) was injected into the rvlm and a retrograde tracer,

75 Biotinylated dextran amine (BDA) was injected into the somato-motor cortex to trace

76 terograde tracer biotinylated dextran amine (BDA) was injected into the ventrolateral PAG, and labele

77 erograde tracer, biotinylated dextran amine (BDA) was iontophoresed bilaterally into the caudal NTS t

78 Thus, biotinylated dextran amine (BDA) was iontophoretically injected into the ventral med

79 Tracing with biotinylated dextran amine (BDA) was used to assess intra-SI projections of adult ra

80 Biotinylated dextran amine (BDA) was used to label the corticostriatal projection fr

81 trograde tracer, biotinylated dextran amine (BDA) were injected into localized regions of the caudal

82 al injections of biotinylated dextran amine (BDA) were made into different CNIC regions.

83 in diameter) of biotinylated dextran amine (BDA) were placed in different locations of the primary m

84 techniques with biotinylated dextran amine (BDA) were used to examine the terminal field structure a

85 ade transport of biotinylated dextran amine (BDA) with immunogold-silver labeling of a D2 receptor an

86 the second with biotinylated dextran amine (BDA) with Vector slate grey and 3,3'-diaminobenzidine te

87 traced by using biotinylated dextran amine (BDA), and many BDA-ir boutons were found to contain gala

88 ade tracing with biotinylated dextran amine (BDA), and retrograde tracing with fluorescent pseudorabi

89 as achieved with biotinylated dextran amine (BDA), and the MOR was detected by using antipeptide MOR

90 oxidase (HRP) or biotinylated dextran amine (BDA), but large percentages of efferent neurons were fou

91 r the other with biotinylated dextran amine (BDA)-3000 molecular weight.

92 terograde tracer biotinylated dextran amine (BDA).

93 han tracing with biotinylated dextran amine (BDA).

94 the widely used biotinylated dextran amine (BDA).

95 inin (PHA-L) and biotinylated dextran amine (BDA).

96 terograde tracer biotinylated dextran amine (BDA).

97 unit B (CTB) and biotinylated dextran amine (BDA).

98 nce of mini-ruby biotinylated dextran amine (BDA).

99 terograde tracer biotinylated dextran amine (BDA).

100 Using biotinylated dextran amine (BDA)/biocytin injections, we describe the cortical proje

101 anterogradely by biotinylated dextran amine (BDA)10k injection into the contralateral motor or primar

102 nsported form of biotinylated dextran amine (BDA; 10,000 molecular weight) in the pigeon dorsal palli

103 Then, biotinylated dextran amine (BDA; 10,000 MW) was injected in the center of the PMv di

104 We deposited biotinylated dextran amine (BDA; 3,000 MW), a retrograde tracer, unilaterally into t

105 ade transport of biotinylated dextran-amine (BDA) delivered to incisions made across the nerve fiber

106 ns of the tracer biotinylated dextran-amine (BDA) into the ventrolateral white matter at T9.

107 s of biocytin or biotinylated dextran-amine (BDA) were made into the guinea pig trigeminal ganglion,

108 inylated tracers biocytin and dextran-amine (BDA) with glutamate immunohistochemistry.

109 I, biocytin, and biotinylated dextrin amine (BDA).

110 of anterograde (biotinylated dextran amine; BDA) and retrograde (cholera toxin B) tracers where RTN

111 r injections of biotinylated dextran amines (BDA) in seven auditory cortical areas.

112 nin (PHA-L) and biotinylated dextran amines (BDA)] tracers were employed to study the putative connec

113 lliei, by using biotinylated dextran amines (BDA, 3,000 MW).

114 To apply Bayesian decision analysis (BDA) to cancer therapeutics to choose an alpha and sampl

115 rved in all cases examined, for both AAV and BDA.

116 Terminal labeling after biocytin and BDA injections into the ganglion was found to be most de

117 ely normal patterns of both CO densities and BDA-labelled intracortical projections.

118 Both DiI and BDA revealed primary olfactory projections to the olfact

119 SII contained at least two row-like FR- and BDA-labeled strips that formed mirror image representati

120 ate parts of the same SI barrel row, FR- and BDA-labeled terminals tended to merge into a single stri

121 ntary interdigitating patches of WGA-HRP and BDA labeling were found primarily in transitional border

122 emical reaction for visualization of HRP and BDA, the BDA-labeled fibers and terminals were seen dist

123 njected into the dentate gyrus and PHA-L and BDA were injected into the entorhinal cortex to determin

124 a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivi

125 oplastic graft material in bone defect area (BDA) reduction of 2-wall defects.

126 method to assess biliary duct number, area (BDA), portal vein area, and total area of each portal fi

127 l cortical regions, produced varicose axonal BDA labeling in a patch-like distribution in the dorsome

128 Approximately 64% of synapses between BDA-labeled boutons and HRP-labeled motoneurons were asy

129 present in 19% of the dendrites contacted by BDA-labeled terminals but were present rarely in both th

130 area 7a), 94.2% of the synapses furnished by BDA-labeled intrinsic collaterals of supragranular pyram

131 that were in register with those labeled by BDA injections into the MGV.

132 One hundred sixty-eight appositions made by BDA-labeled terminals on HRP-labeled motoneurons were se

133 rm nucleus (Uva), which was substantiated by BDA injections into Uva that labeled terminals in Av.

134 Combined BDA-366 and RAD001 treatment exhibits strong synergy aga

135 opy showed that in these patch compartments, BDA labeling was present exclusively in axons and termin

136 We computed BDA-optimal parameters for the 23 most common cancer sit

137 ng NCI and Alliance data, and then computing BDA-optimal type 1 error rates and sample sizes for onco

138 ents, and high prevalence, the corresponding BDA-optimal error rates were much lower, in some cases e

139 the lateral CST ipsilateral to the cortical BDA injection, and 87.9 +/- 1.0% of total CST axons proj

140 y at all cervical levels, particularly dense BDA labeling was observed in laminae VIII and IX ipsilat

141 ly by injecting a mixture of biotin dextran (BDA) with 3H-amino acids into the affected eye immediate

142 ract-tracing with biotinylated dextranamine (BDA) and fluorescence immunohistochemistry visualized wi

143 dely labeled with biotinylated dextranamine (BDA).

144 Dual BDA and ZAP-70 positivity had a median OS of 84 months (

145 Under light microscopical examination, BDA-labeled terminals were observed closely apposing the

146 urons showed that after MSC treatment, fewer BDA-positive fibers crossed the CC and extended into the

147 However, BDA did not correlate with Bax protein levels: BDA posit

148 However, BDA reduction was statistically greater in group 2 (48.8

149 agglutinin-horseradish peroxidase (WGA-HRP), BDA, or a fluorescent tracer, iontophoretically injected

150 In BDA-labeled tissue prepared for electron microscopic ana

151 with PD reduction, CAL gain, and changes in BDA in both groups, which was statistically significant

152 r, and the highly specific calpain inhibitor BDA-410 restored normal synaptic function both in hippoc

153 alamocortical terminals labeled by injecting BDA into the ventroposterolateral nucleus (VPL) were obs

154 ormed double-labeling experiments, injecting BDA in the CRNs and subunit B of the cholera toxin or Fl

155 At 20-23 d after injury, BDA-labeled CST axons did not extend past the lesion exc

156 Some double-labeled BDA/VGAT varicosities were seen apposed to small somata

157 copy for the presence of peroxidase-labeled, BDA-containing vagal afferents and immunogold MOR labeli

158 A did not correlate with Bax protein levels: BDA positive and negative cases had high and low baselin

159 g biotinylated dextran amine (BDA), and many BDA-ir boutons were found to contain galanin immunoreact

160 an amine (BDA) in the area of the rVRG, many BDA-labeled terminals in the ventral horn of cervical sp

161 Under electron microscopy BDA-labeled boutons containing clear, spherical synaptic

162 By electron microscopy, BDA- or PHA-L-labeled axon terminals originating from th

163 In both models, BDA- and NPY-colabeled fibers were limited mainly to the

164 trastructural examination revealed that most BDA-labeled terminals contained clear spherical vesicles

165 Of 173 observed BDA-labeled vagal afferent axon terminals, 33% contained

166 respectively, a higher density (P < 0.05) of BDA(+) fibers was found in thoracic dorsal gray matter o

167 Within RTN, 51% of BDA-labelled axonal varicosities contained detectable le

168 Approximately 57% and 62% of BDA-labeled terminals originating from the medial (n=150

169 We found that daily administration of BDA-410, a calpain-1 inhibitor, strikingly ameliorated m

170 To assess the functional association of BDA injection sites in the ITN, the known topographical

171 mine (BDA) into the PVH produced clusters of BDA-positive nerve terminals within the ipsilateral RVLM

172 ions were processed for the demonstration of BDA or CO.

173 the ipsilateral XII, the highest density of BDA labeling was found in the dorsal compartment and the

174 ent whisker barrel rows, the distribution of BDA- and FR-labeled terminals in the neostriatum followe

175 r tangential sectioning, the distribution of BDA-labeled cell bodies and terminal boutons was documen

176 ions of the retrogradely transported form of BDA (3,000 molecular weight) in the pigeon dorsal thalam

177 s, labelled by an in vivo focal injection of BDA, were examined using correlated light and electron m

178 Precise iontophoretic injections of BDA and CTB in the mSCN and vSCN were used to identify e

179 abeled anterogradely following injections of BDA in the VCN.

180 Discrete injections of BDA into auditory cortex labeled bands of neurons in the

181 Small injections of BDA were made in the anterior cingulate, medial agranula

182 Finally, after injections of BDA, a small number of retrogradely labeled pyramidal ne

183 ere processed for peroxidase localization of BDA and gold-silver labeling of tyrosine hydroxylase (TH

184 Instead, the majority of BDA-labeled fibers in the rRPa were orexin positive.

185 Measurement of BDA-labeled terminals in the spinal cord gray matter rev

186 Discrete microinjections of BDA were placed into either the medial or lateral aspect

187 mentary patterns of anterograde migration of BDA and 3H label in the cut and intact retinal axons, re

188 after injury, however, a novel population of BDA-labeled CST axons could be seen extending from the g

189 The proportions of BDA-labeled axon terminals forming asymmetric synapses w

190 Serial section reconstruction of BDA-labeled corticothalamic neurons in VIa revealed pyra

191 that AAV has actions equivalent to those of BDA as an anterograde tracer and is suitable for analysi

192 y of neurons infected compared with those of BDA.

193 Anterograde transport of BDA from injections into the PBN and KF nuclei of rabbit

194 Among the biliary QT, only BDA correlated with the renal QT (P < 0.01).

195 Injections of the tracers PHA-L or BDA into these auditory-responsive posterior thalamic nu

196 In contrast to the other pathways, BDA-labeled ascending sensory axons did extend into and

197 cal attachment level (CAL), and radiographic BDA were done at the baseline and 6-month postoperative

198 Specifically in lactating rats, BDA-and NPY-colabeled axonal swellings were in close app

199 The PPNd also contained retrogradely BDA-labeled neurons which were contacted by anterogradel

200 synthesized from tartrates employing Ley's "BDA" and "Dispoke" methodologies as the key step.

201 Finally, we combined selective BDA labeling of IT-type or PT-type terminals with immuno

202 Although some BDA-labeled axons with varicosities were found bilateral

203 treatment (16 vs 156 months, P = .029) than BDA negative cases.

204 tron microscopic observations indicated that BDA-labeled boutons form asymmetric synapses mainly on 0

205 The BDA assay measures the intrinsic ubiquitin/proteasome ac

206 The BDA-labeled axons in the ventral column were on the same

207 The BDA-labeled fibers were seen descended along Probst' tra

208 The BDA-labeled neurons in deep layer V and layer VI of the

209 action for visualization of HRP and BDA, the BDA-labeled fibers and terminals were seen distributing

210 Approximately 19% of the BDA and PHA-L axon terminals examined originating from t

211 ach target region, a large percentage of the BDA-ir varicosities was VGLUT2-ir (41-83%).

212 Thirty percent of the BDA-labeled terminals formed asymmetric excitatory synap

213 existing treatments, and low prevalence, the BDA-optimal type 1 error rates were much higher than the

214 re more dense on the side ipsilateral to the BDA deposit, and both A7 and locus coeruleus neurons rec

215 processed sequentially for WGA-HRP, and then BDA immunohistochemistry using two different chromogens.

216 Many of these BDA-labeled terminals formed asymmetric, excitatory-type

217 Two hundred and sixty-five of these BDA-labeled terminals were examined at the ultrastructur

218 Within the A lamina of the dLGN, this BDA labeling allowed us to distinguish Y retinogeniculat

219 he midbrain by injecting the neuronal tracer BDA into different branches of the lateral line nerve an

220 horetic injection of the anterograde tracers BDA, neurobiotin and PHA-L in the host.

221 Although traditional BDA tracing cannot reliably visualize regenerating ngr1(

222 One hundred and twelve BDA-labeled axon terminals were observed synapsing with

223 Adult female grass rats received unilateral BDA injections directed at the SCN or vSPVZ and their br

224 racterize the LRN projection to the CN using BDA injections.

225 ompartment of the ventral compartment, where BDA labeling formed a dense, patchy distribution.

226 r accounts using different tracers, but with BDA they are labeled more fully.

227 serotype 1) was systematically compared with BDA as an anterograde tracer by injecting both tracers i

228 GFP is 10 times more efficient compared with BDA.

229 eled with BDA, sometimes doubly labeled with BDA and (3)H-leucine, were in close apposition with dend

230 Axons and swellings labeled with BDA and olivocochlear neurons labeled with CTB were immu

231 ntrolateral medullary efferents labeled with BDA were apposed to thoracic reticulospinal neurons labe

232 We found that swellings labeled with BDA, sometimes doubly labeled with BDA and (3)H-leucine,

233 Double labeling with BDA and (3)H-leucine signifies that the label was antero

234 ent of contralesional rewiring measured with BDA and PRV tracing was related to sensorimotor dysfunct

235 Patients with BDA positive cells had a shorter median overall survival

236 Anterograde tracing with BDA demonstrated that RVLM and MCVA are interconnected.